Abstract
US demand to rise over 17% annually through 2011
US demand for nanotechnology health care products will grow over 17 percent
per year to $50 billion in 2011. Afterwards, the increasing flow of new
nanomedicines, nanodiagnostics, and nanotech-based medical supplies and
devices into the US marketplace will boost demand to $107 billion in 2016 and
$225 billion in 2021. The critical need for new or improved therapies for many
medical conditions will promote the adaptation of nanotechnology to an
expanding number of pharmaceuticals. The total market for nanomedicines will
command strong growth over the long term, rising to $41 billion in 2011, $84
billion in 2016 and $175 billion in 2021. Treatments based on humanized
monoclonal antibodies, nanopolymers and nanoproteins will drive gains, with
compounds for cancer, neurological disorders, viral infections and ischemic
heart diseases leading new product introductions and growth opportunities.
Eventually, pharmaceutical applications of nanotechnology will extend into all
major therapeutic classes, encompassing numerous formulations and delivery
systems.
Nanodiagnostics to grow 13% per year through 2011
Advances in nanotechnology will also contribute significant improvements to
the quality and performance of medical diagnostic products. Nanosized labels,
probes and biosensors will greatly enhance the speed, accuracy, capabilities
and cost-effectiveness of in vitro diagnostic testing, drug discovery and
medical research procedures. Nanoparticle formulations of superparamagnetic
iron oxide, gadolinium, perfluorocarbon and specialty polymers will broaden in
vivo imaging capabilities by enabling the detection of tumors, plaque, genetic
defects and other disease states at much earlier stages and with lower, safer
concentrations of injected compounds. Reflecting these advantages and new
offerings, demand for nanodiagnostic products is projected to increase over 13
percent per year to 2011 and continue rising at a double digit annual pace
through 2021.
View Cart
